

SEQUENCE LISTING

<110> Takeda Pharmaceutical Company Limited
 YOSHIKAWA, MASATO
 SAITOH, MORIHISA
 KATO, TAISUKE
 YOSHITOMI, YAYOI
 SEKI, TOMOHIRO
 NAKAGAWA, YASUO
 TOMINARI, YUSUKE
 SETO, MASAKI
 SASAKI, YUSUKE
 OKANIWA, MASANORI
 ODA, TSUNEO
 SHIBUYA, AKITO
 HIDAKA, KOSUKE
 SHIOKAWA, ZENYU
 MURATA, SHUMPEI
 OKABE, ATSUTOSHI
 NAKADA, YOSHIHISA
 MOCHIZUKI, MICHIO
 FREEZE, BRIAN SCOTT
 TAWARAISHI, TAISUKE
 WADA, YASUFUMI
 GREENSPAN, PAUL D.

<120> CYCLIC DINUCLEOTIDE

<130> 3817.040PC03

<150> US 62/589,300

<151> 2017-11-21

<150> JP 2017-107216

<151> 2017-05-30

<150> JP 2016-234553

<151> 2016-12-01

<160> 14

<170> PatentIn version 3.5

<210> 1

<211> 449

<212> PRT

<213> Artificial Sequence

<220>

<223> Antibody 1 heavy chain

<400> 1

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Phe Gly Gly Ser Phe Ser Gly Tyr
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Asn His Arg Gly Asn Thr Asn Asp Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ala Leu
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Arg Glu Arg Gly Tyr Thr Tyr Gly Asn Phe Asp His Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys
210 215 220

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
Page 2

225		230		235		240									
Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser
			245						250					255	
Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp
			260					265					270		
Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn
		275					280					285			
Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val
	290					295					300				
Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu
305					310					315					320
Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys
				325					330					335	
Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr
			340					345					350		
Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr
		355					360					365			
Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu
	370					375					380				
Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu
385					390					395					400
Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys
				405					410					415	
Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu
			420					425					430		
Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly
	435						440					445			

Lys

<210> 2
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<223> Antibody 1 light chain

<400> 2

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Gly Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Lys Thr Trp Pro Arg
85 90 95

Thr Phe Gly Gln Gly Thr Asn Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
Page 4

165

170

175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205

Phe Asn Arg Gly Glu Cys
 210

<210> 3
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> C-hTME(139aa)-F Primer

<400> 3
 cctggcccca gctgagatct ctg 23

<210> 4
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> hTME173(H232R)-R Primer

<400> 4
 gtaaaccgga tccttgatgc cagcacgggc accgggc 37

<210> 5
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> hTME173(H232R)-F Primer

<400> 5
 ctgccccagc agaccgggtga ccgtgctggc atcaag 36

<210> 6
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> hTMEM173-st-Not-R Primer

 <400> 6
 ataatagcgg ccgctcaaga gaaatccgtg cggagagg 38

 <210> 7
 <211> 53
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> C-FLAG-Bam-hTMEM173(139aa)-F Primer

 <400> 7
 cgactacaag gacgacgatg acaagggatc cctggcccca gctgagatct ctg 53

 <210> 8
 <211> 62
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> HA-Bam-ko-hTMEM173-F Primer

 <400> 8
 gtaccatac gatgttccag attacgctgg atccgccacc atgccccact ccagcctgca 60
 tc 62

 <210> 9
 <211> 51
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Xba-Eco-ko-HA-F Primer

 <400> 9
 ataatatcta gaattcgcca ccatgtaccc atacgatgtt ccagattacg c 51

 <210> 10
 <211> 48
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Bam-ko-hTME173v1-F Primer

 <400> 10

ttccagatta cgctggatcc gccacatgc cccactccag cctgcatc 48

<210> 11
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> hTME173-st-Not-R2 Primer

<400> 11
cctctagact cgagcggccg ctcaagagaa atccgtgcgg agagg 45

<210> 12
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Nhe-ko-HA-F Primer

<400> 12
ggagaccaa gctggctagc gccacatgt acccataga tg 42

<210> 13
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> CMVPro-BglIII-F Primer

<400> 13
ataataagat ctgttgacat tgattattga ctagttatta atag 44

<210> 14
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> CMVPro-HindIII-R Primer

<400> 14
ataataaagc ttgagctctg cttatataga cctccc 36